Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan [3]

Leukemia

Volumn 22, Issue 2, 2008, Pages 428-432

  Narimatsu, H ^a,b   Yokozawa, T ^c   Iida, H ^d   Tsuzuki, M ^e   Hayakawa, M ^f   Takeo, T ^g   Iino, M ^h   Ichihashi, T ⁱ   Kato, C ^c   Sawamoto, A ^a   Sao, H ^d   Yanada, M ^b   Emi, N ^e   Kiyoi, H ^j   Yamaguchi, T ⁱ   Naoe, T ^b   Suzuki, R ^j   Sugiura, I ^a  

^a TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d Meitetsu Hospital   (Japan)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KOMAKI CITY HOSPITAL   (Japan)

^g Yokkaichi Municipal Hospital   (Japan)

^h Yamanashi Prefectural Central Hospital   (Japan)

ⁱ Okazaki City Hospital   (Japan)

^j NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; HYBRID PROTEIN; IDARUBICIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENDER BIAS; HUMAN; JAPAN; KARYOTYPING; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 39149086382     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404905     Document Type: Letter

References (8)

1. Ferrara F, Del Vecchio L. Acute myeloid - leukemia with t(8;21)/AML1/ ETO: A distinct biological and clinical entity. Haematologica 2002; 87: 306-319.
2. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J et al Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17 3767-3775.
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
4. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717.
5. Nishii K, Usui E, Katayama N, F Lorenzo V, Nakase K, Kobayashi T et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: Concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 2003; 17: 731-737.
6. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 2002; 99: 3517-3523.
7. Schlenk RF, Benner A, Krauter J, Buchner T, Squerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750.
8. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135: 165-173.